Duration of the study Sample Clauses

Duration of the study. The active study phase for each patient is 180 days. Enrolment is expected to begin in Q1 2008; the study is expected to end X0 0000. 10 Data Handling and Record Keeping
Sample 1Sample 2Sample 3See All (7)
AutoNDA by SimpleDocs
Duration of the study. The [***] is [***] to be [***]r. Any [***] will be [***] to [***] at that time.
Sample 1
Duration of the study. The study that is the subject matter of this agreement may begin once the pertinent permits and administrative authorizations have been obtained, from the date it is signed, and will have an estimated duration of <<xxxxxx>> months from the start thereof. If recruitment has not been completed within the appropriate time frames, the contracting parties shall adopt, by mutual agreement, such provisions as they may deem appropriate. The study shall be suspended before its completion, by written notification, if any of the following circumstances should arise: Due to the principal investigator’s noncompliance with the terms of this agreement. If compliance with the protocol is deficient or the data recorded is repeatedly inaccurate or incomplete. By mutual agreement in writing among the contracting parties. If the Sponsor decides to terminate or suspend it for business reasons or for not being able to complete it due to a lack of patients or centers. The Sponsor shall prepare a report explaining the reasons for suspending the study. If the study should be suspended, the sponsor shall notify all the appropriate health authorities and the participating centers’ CRECs of the suspension.
Sample 1
Duration of the study. The patients will be clinically followed throughout the course of their hospital admission. The data collected during surgery and postoperative course will be used to evaluate the efficacy of the MvIGS spine navigation system. As designed, a total of 130 patients are to be enrolled in the study, with 65 patients per treatment group. Based on this sample size, rate of patient accrual, and the prescribed follow- up time, the total duration of the study is projected to be approximately 9 months.
Sample 1
Duration of the study. Following a Screening Visit, at Baseline Visit (Day 0) the study eye will receive injection of RBM-007. The primary study endpoint will be at 28 days after RBM-007 injection, at which time anti-VEGF treatment can be resumed according to the investigating physician. Follow up will continue to the exit visit at 56 days. Diagnosis and Main Criteria for Inclusion: • Provide signed written informed consent on the IRB / EC approved Informed Consent Form (ICF) and provide authorization as appropriate for local privacy regulations. • Male or female 55 years of age or older on the date of signing the ICF and able and willing to comply with all treatment and follow-up study procedures. At Screening Visit, subjects must meet all the following inclusion criteria: • Must have had prior treatment in the study eye with any intravitreal anti-VEGF medication (at least 3 anti- VEGF treatments within the prior 2-6 months), throughout which clinical examination and SD-OCT imaging has shown recurrent or persistent exudative activity, as shown by the presence of intraretinal or subretinal fluid, and/or subretinal exudation or hemorrhage. • BCVA of 65 to 10 ETDRS letters (20/50 to ≥20/640) in the study eye. • Presence of significant subretinal fluid and/or cystoid macular edema secondary to exudative age-related macular degeneration as assessed by SD-OCT in the study eye, with a minimum of 300 µm within the central subfield. • Total lesion size of ≤9 disc areas, lesion containing ≤50% hemorrhage in the study eye. • Reasonably clear media and reasonable fixation ability in the study eye to allow for good quality SD-OCT and fundus photography. At Baseline Visit (Day 0), subjects must meet all the following inclusion criteria: • BCVA of 65 to 10 ETDRS letters (20/50 to ≥20/640) in the study eye. • Presence of significant subretinal and/or intraretinal fluid secondary to exudative age-related macular degeneration as assessed by SD-OCT in the study eye, with a minimum of 300 µm within the central subfield. • Total lesion size of ≤9 disc areas, lesion containing ≤50% hemorrhage in the study eye. Study Eye If both eyes of a subject meet the eligibility criteria, then study eye will be determined as the eye with the worse vision. If both eyes have the same vision, the right eye (OD) should be determined as the study eye. Investigational product, dosage and mode of administration: Subjects will receive one of the following three dose levels of the investigational product, RBM-007 injecta...
Sample 1

Related to Duration of the study

  • Establishment and Purpose The Plan was adopted by the Board of Directors on October 28, 2012, and shall be effective immediately prior to the closing of the initial offering of Stock to the public pursuant to a registration statement filed by the Company with the Securities and Exchange Commission (the “Effective Date”). The purpose of the Plan is to promote the long-term success of the Company and the creation of stockholder value by (a) encouraging Employees, Outside Directors and Consultants to focus on critical long-range objectives, (b) encouraging the attraction and retention of Employees, Outside Directors and Consultants with exceptional qualifications and (c) linking Employees, Outside Directors and Consultants directly to stockholder interests through increased stock ownership. The Plan seeks to achieve this purpose by providing for Awards in the form of restricted shares, stock units, options (which may constitute incentive stock options or nonstatutory stock options), stock appreciation rights or cash-based awards.

  • Duration and Termination of this Agreement This Agreement shall remain in force until March 1, 1998, and continue in force from year to year thereafter, but only so long as such continuance is specifically approved at least annually (a) by the vote of a majority of the Trustees who are not parties to this Agreement or interested persons of any party to this Agreement, cast in person at a meeting called for the purpose of voting on such approval, and (b) by the Trustees of the Trust, or by the vote of a majority of the outstanding voting securities of the Fund. The aforesaid requirement that continuance of this Agreement be "specifically approved at least annually" shall be construed in a manner consistent with the 1940 Act and the rules and regulations thereunder and any applicable SEC exemptive order therefrom. This Agreement may be terminated with respect to the Fund at any time, without the payment of any penalty, by the vote of a majority of the outstanding voting securities of the Fund or by the Trust's Board of Trustees on 60 days' written notice to you, or by you on 60 days' written notice to the Trust. This Agreement shall terminate automatically in the event of its assignment. This Agreement may be terminated with respect to the Fund at any time without the payment of any penalty by the Board of Trustees or by vote of a majority of the outstanding voting securities of the Fund in the event that it shall have been established by a court of competent jurisdiction that you or any of your officers or directors has taken any action which results in a breach of your covenants set forth herein.

  • Duration of Trust Unless terminated as provided herein, the Trust shall have perpetual existence.

  • DURATION, TERMINATION AND AMENDMENT OF THIS AGREEMENT This Agreement shall become effective on the date first above written and shall govern the relations between the parties hereto thereafter, and shall remain in force until December 29, 2002 on which date it will terminate unless its continuance after December 29, 2002 is "specifically approved at least annually" (i) by the vote of a majority of the Trustees of the Trust who are not "interested persons" of the Trust or of the Adviser at a meeting specifically called for the purpose of voting on such approval, and (ii) by the Board of Trustees of the Trust, or by "vote of a majority of the outstanding voting securities" of the Fund. This Agreement may be terminated at any time without the payment of any penalty by the Trustees or by "vote of a majority of the outstanding voting securities" of the Fund, or by the Adviser, in each case on not more than sixty days' nor less than thirty days' written notice to the other party. This Agreement shall automatically terminate in the event of its "assignment". This Agreement may be amended only if such amendment is approved by "vote of a majority of the outstanding voting securities" of the Fund.

  • Examination of the Agreement A copy of this Agreement shall be available at all reasonable times at the office of the Warrant Agent in the Borough of Manhattan, City and State of New York, for inspection by the Registered Holder of any Warrant. The Warrant Agent may require any such holder to submit his Warrant for inspection by it.

  • of the Standard Terms (b) The Company hereby represents and warrants to the Trustee for the benefit of Certificateholders that as of the Closing Date (or, if otherwise specified below, as of the date so specified):

  • Duration Termination 1. This License Agreement is concluded for an indefinite period, subject to termination in accordance with the provisions of article 6.2 and 6.3. Except based on these provisions, parties are not allowed to terminate the License Agreement.

  • Duration and Termination of the Agreement This Agreement shall become effective upon its execution; provided, however, that this Agreement shall not become effective unless it has first been approved (a) by a vote of the Independent Trustees, cast in person at a meeting called for the purpose of voting on such approval, and (b) by an affirmative vote of a majority of the outstanding voting shares of the Fund. This Agreement shall remain in full force and effect continuously thereafter, except as follows:

Time is Money Join Law Insider Premium to draft better contracts faster.